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Abstract
Patients with clinical manifestations of leishmaniasis, including cutaneous leishmaniasis, have limited treatment options,
and existing therapies frequently have significant untoward liabilities. Rapid expansion in the diversity of available
cutaneous leishmanicidal chemotypes is the initial step in finding alternative efficacious treatments. To this end, we
combined a low-stringency Leishmania major promastigote growth inhibition assay with a structural computational filtering
algorithm. After a rigorous assay validation process, we interrogated ,200,000 unique compounds for L. major
promastigote growth inhibition. Using iterative computational filtering of the compounds exhibiting .50% inhibition, we
identified 553 structural clusters and 640 compound singletons. Secondary confirmation assays yielded 93 compounds with
EC50s # 1 mM, with none of the identified chemotypes being structurally similar to known leishmanicidals and most having
favorable in silico predicted bioavailability characteristics. The leishmanicidal activity of a representative subset of 15
chemotypes was confirmed in two independent assay formats, and L. major parasite specificity was demonstrated by
assaying against a panel of human cell lines. Thirteen chemotypes inhibited the growth of a L. major axenic amastigote-like
population. Murine in vivo efficacy studies using one of the new chemotypes document inhibition of footpad lesion
development. These results authenticate that low stringency, large-scale compound screening combined with
computational structure filtering can rapidly expand the chemotypes targeting in vitro and in vivo Leishmania growth
and viability.
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Introduction
Leishmaniasis is endemic in .85 developing countries with
.1.5 million estimated cases occurring each year and an
additional 350 million people at risk of infection [1]. Increased
travel and migration within the tropics, subtropics, Middle East
and Southern Europe as well as global climate and environmental
changes are making leishmaniasis a considerable risk for
populations in geographic regions previously unaffected by the
disease [2–5]. As a result, there has been a progressive expansion
of leishmaniasis endemic regions as well as a concomitant increase
in the total number of reported leishmaniasis cases, often in
epidemic proportions (i.e., with 100,000–200,000 individuals
infected) [6–9]. Transmission of leishmaniasis most commonly
occurs via an infected phebotomine sandfly. Leishmaniasis can
also be transmitted, albeit rarely, through blood transfusions,
especially to individuals with immature or compromised immune
systems, further expanding and globalizing the number of at-risk
populations [10]. With clinical manifestations ranging from
cutaneous (CL) and mucocutaneous (M-CL) to visceral, leishman-
iasis has profound cultural and socioeconomic repercussions due to
overt disability, disfigurement or scarring, and death [4,11–15].
Despite the prevalence of leishmaniasis and its impact on
human life, there are no vaccines or prophylactic drugs for any
form of the disease. Current chemotherapeutic treatments rely
heavily on the use of the pentavalent antimonials, sodium
stibogluconate, and meglumine antimoniate, which were first
introduced more than a half century ago [16–18]. Significantly,
these compounds have been used without refinement for decades,
have serious side effects and are declining in efficacy due to
chemoresistance [19–22]. Second-line drugs, such as pentamidine
and amphotericin B, are available but they too have significant
untoward effects and pharmacological liabilities [4,18]. Moreover,
these existing leishmanicidals often require continuous clinical
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surveillance, have invasive or painful routes of administration and,
are expensive for endemic areas. Others have attempted to
augment the pool of available leishmanicidals by exploiting drugs
approved for other diseases. Among newer treatments are the use
of rifampicin, tamoxifen, doxocycline, monomycine, trimethoprim
and nifurtimox; however, these agents are generally associated
with limited anti-leishmanial efficacy [18,23–29]. To maximize
effectiveness and minimize toxicity, the choice of drug dosage and
duration of therapy should be individualized based on the region
of disease acquisition and host factors such as immune status. Also,
we know that some drugs and regimens are effective only against
certain Leishmania species or strains and only in certain areas of the
world. The idea that one drug might treat all forms of
leishmaniasis has rapidly lost popularity. Regrettably, there is a
paucity of large-scale drug discovery efforts focusing on the design
of new small molecules (i.e. drugs) that can treat individuals with
leishmaniasis. This deficiency has contributed to leishmaniasis
being classified as a neglected disease, with CL being the most
neglected among the clinical manifestations of leishmaniasis [13].
Thus, there is a strong need to identify potential new drug
treatments for specific clinical manifestations of leishmaniasis, and
especially novel chemotherapeutics for CL.
As with other pathogenic diseases, genetic tools and genomic
sequencing information are now available for multiple Leishmania
spp. enabling a molecular target- driven approach to anti-
leishmanial drug discovery [30–32]. Nonetheless, the low success
rate of those efforts may reflect an incomplete understanding of the
complexities of leishmaniasis and the significance of the proposed
molecular targets to parasite growth or survival [33,34]. Thus,
whole parasite phenotypic anti-leishmanial drug discovery remains
appealing. Until recently, however, most efforts to identify new
leishmanicidals via whole parasite screening have concentrated on
the exploitation of limited, small-scale activities using discrete,
focused compound sets or compounds with known pharmacolog-
ical actions [35,36]. Consequently, the identification of novel
leishmanicidal chemotypes has been effectively limited by
screening throughput as well as compound library diversity. We
postulate that the identification of new anti-leishmanial chemo-
types can be rapidly accelerated by using low stringency, high
throughput screening (HTS) methodologies with large diverse
compound libraries combined with computational tools. For
maximum utility, the HTS assays should be well-validated,
integrated with data management and capture systems, have a
simple assay format, be relatively inexpensive and, be coupled with
secondary assays to expedite confirmation of the activity and
specificity of novel chemotypes [37–39].
In the work presented herein, we developed and implemented a
multi-tiered compound screening paradigm to identify and
confirm novel leishmanicidal chemotypes. Our screening strategy
was founded on a validated L. major (taxonomy id 5664)
promastigote drug susceptibility HTS assay, which we used to
screen a structurally diverse 196,146 compound library at low
stringency (i.e., a relatively high compound screening concentra-
tion - 10 mM). Promastigotes are easy to use and there is evidence
that they provide a good model for gauging a compound’s
leishmanicidal activity [40–42]. The selected assay detection
reagent, alamar blue, is simple, inexpensive, easily adapted to
automated HTS procedures and has been frequently used to
identify and characterize leishmanicidal compounds [43,44]. Our
primary aim was to maximize the potential chemical diversity of
the L. major promastigote growth inhibitory chemotypes identified.
Thus, we purposefully screened a large chemical library at a
relatively high initial compound concentration to yield the
maximum number of active compounds. To reduce the candidate
compounds to a manageable size, we exploited computational
methods to cluster chemotypes. We termed this integrated
approach HILCES for high throughput, low-stringency, compu-
tationally enhanced small molecule screening. Representative
members of each cluster and the unassigned compounds, i.e.
singletons, were then sequentially characterized with respect to
potency, specificity of response, and predicted in silico ADMET.
Significantly, the use of an annotated public compound library
enabled us to determine compound specificity by comparing its
bioactivity in up to 369 additional biochemical or phenotypic
assays. Moreover, specific molecular targets were suggested that
might be critical to Leishmania growth, viability and survival.
Selected compounds also demonstrated in vivo efficacy in a murine
model system.
Materials and Methods
Chemicals and reagents
Black, clear bottom tissue culture treated 384-well microtiter
plates were purchased from Greiner (Monroe, NC) and used for all
experiments. Alamar blue (Cell Titer Blue) was purchased from
Promega (Madison, WI); tamoxifen from MP Biomedicals (Solon,
OH); dimethyl sulfoxide (DMSO), aphidicolin from Sigma-Aldrich
(St. Louis, MO); phenyltoloxamine, clotrimazole, sangivamycin
and amphotericin B from VWR (West Chester, PA); disulfiram
from Fisher Scientific (Pittsburgh, PA); pentamidine from Toronto
Research Chemicals (Ontario, Canada) and; acivicin from Biomol
(Plymouth Meeting, PA). The PubChem CID compounds 786799,
742546, 760847, 2946668, 757789, 2851545, 728862, and
16187595 were obtained from Chembridge (San Diego, CA). All
purchased compounds were subjected to quality control testing by
their respective manufacturers.
Routine L. major parasite culturing and counting
L. major promastigotes (MHOM/SA/85/JISH118) (a kind gift
from Dr. Frederick Buckner) were maintained in Medium 199
(pH 7.2) (Invitrogen, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT),
Author Summary
Leishmaniasis is a parasitic disease with cutaneous,
mucocutaneous and visceral clinical manifestations, de-
pending on the Leishmania spp. and human host. Globally,
there are 350 million people at risk of leishmaniasis, but
current treatment options rely predominantly on ancient
pentavalent antimonials, which have the potential to
cause serious systemic toxicity. Our research focuses on
the rapid expansion of potential anti-leishmanial com-
pounds that could function as novel chemical structures
for future drug development and offer additional thera-
peutic options to patients with leishmaniasis. We com-
bined high throughput screening methodologies with
computational algorithms and multiple confirmatory assay
formats to identify and characterize new potent L. major
promastigote growth inhibitors, including one that dis-
plays in vivo activity without toxicity to human cells. Our
use of a large, broadly distributed compound library
enabled the identification of these new chemotypes. In
addition, since this chemical library is publicly available
and annotated, we were able to cross-query archived
bioassays and to identify new molecular targets that may
be involved in L. major growth and viability as well as
identify new protein targets for future leishmanicidal drug
discovery.
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penicillin (100 units/mL) and streptomycin (100 mg/mL) as
previously described in Buckner and Wilson [45]. Promastigotes
were grown in vented T75 tissue culture flasks and maintained at
28uC. Promastigote cultures were initiated at 105 parasites per mL
and subcultured every 3–4 days. L. major promastigote counts were
performed in duplicate using a hemocytometer and particle
counter (Beckman Coulter, Fullerton, CA). For HTS assays,
L. major promastigote cultures were harvested during exponential
growth phase (,2.0–3.06107 parasites/mL) and were not main-
tained past passage 20.
Axenic amastigote-like parasite populations were derived from
stationary growth phase L. major promastigotes and weremaintained
in Schneider’s medium (pH 4.9) supplemented with 10% heat-
inactivated FBS, penicillin (100 units/mL), streptomycin (100 mg/
mL), L-glutamine (2 mM) and cultured at 32uC with 5% CO2. This
parasite population was specifically designed to test the potency of
compounds under low pH conditions. At these culturing conditions
,80–90% of the L. major parasites exhibited an aflagellated rounded
morphology and displayed similar characteristics of previously
described axenic amastigotes including, but not limited to doubling
time (i.e., ,24 h), clustered growth patterns, agglutination response
to PNA lectin, protease activity and protein expression profiles
[46–49]. Characterization of this parasite population also includes
genotyping studies to confirm identity. All axenic amastigote-like
parasite cultures were maintained in vented T25 or T75 flasks. For
drug susceptibility assays, axenic amastigote-like parasites were
harvested in exponential growth phase.
Compound libraries
The library of pharmacologically active compounds (LOPAC)
(1,280 compounds) was purchased from Sigma-Aldrich. The DP
validation set (159 compounds) and the University of Pittsburgh
Chemical Methodology and Library Development Center (UP-
CMLD) diversity set (960 compounds) were obtained from the
UP-CMLD (http://ccc.chem.pitt.edu/UPCMLD/index.html).
We assayed the 196,146 compound library from the Pittsburgh
Molecular Libraries Screening Center (PMLSC) for L. major
growth inhibitors. Cherry-picked compounds from the PMLSC
library were supplied by BiofocusDPI (San Francisco, CA).
Library compound dilution scheme for primary screening
In primary screening, 2 mL of a 1 mM test compound solution
in 100% DMSO were diluted in 22 mL complete L. major
promastigote growth medium, generating an 83.3 mM working
concentration (in 8.3% DMSO) of library compounds. The final
test compound concentration was 10 mM with a constant DMSO
concentration of 1% in each assay well.
Automated primary HTS using L. major drug
susceptibility assay
The L. major promastigote drug susceptibility assay was performed
in a final volume of 25 mL using our previously described 384-well
microtiter plate format [38,39]. For automated HTS procedures, L.
major promastigotes (5,000 parasites/22 mL) in complete growth
medium were seeded into each well of the microtiter plates using a
MAPC2 bulk dispenser (Titertek, Huntsville, AL). Test and control
compounds (3 mL) were added to individual wells using a Velocity 11
V-prep (Menlo Park, CA) liquid handling system, equipped with a
384-well dispensing head, followed by centrifugation at 50 g for
1 min. Negative (vehicle) controls contained 1% DMSO, positive
controls contained 10% DMSO and EC50 controls contained
500 nM tamoxifen (final well concentrations). Assay plates were
allowed to incubate for 44 h at 28uC in the presence of 5%CO2. Five
mL of alamar blue reagent were added to each assay plate well and
incubated for 4 h at 28uC with 5% CO2. Data were captured on a
Molecular Devices SpectraMax M5 (excitation560; emission590).
Individual assay plate Z-factors were derived from the vehicle and
positive controls, and data from plates were used only if Z-factors
were .0.5 [50]. Primary hits were defined as compounds displaying
$50% inhibition of signal readout. The L. major axenic amastigote-
like assay was performed using the alamar-blue assay format and
detection methods as the promastigote except that assay plates
(7,500 parasites/well) were incubated for 144 h at 32uC in the
presence of 5% CO2.
Potency determinations
In initial 10-point EC50 determination experiments, two mL of
1 mM test compound in 100% DMSO were diluted with 46 mL
complete L. major promastigote growth medium creating a
41.7 mM working concentration of library compounds. A two-fold
serial dilution was then performed creating a concentration range
(0.08–41.7 mM). The assays were performed in duplicate with a
final 10-point concentration range spanning 0.01–5.00 mM. A
compound was designated a confirmed inhibitor only if the EC50
values of both replicates were #5 mM.
Flow cytometer-based growth inhibition and cytotoxicity
assays
L. major promastigotes were harvested in exponential growth
phase and adjusted to a concentration of 2.16105 parasites per mL
in complete growth medium. Fifteen thousand parasites (75 mL
volume) were then seeded into each well of a 96 well microtiter
plate and were treated with a concentration range (0.1–50 mM) of
test and control compounds. Parasite assay plates were incubated
for 48 h at 28uC. Samples were prepared by transferring five mL of
parasite suspension to 100 mL of ViaCount reagent (Guava
Technologies, Hayward, CA) followed by gentle and thorough
mixing to ensure an even distribution of parasites. Data were
captured on a Guava EasyCyte Plus flow cytometer and analyzed
using CytoSoft 5.0.2 software (Guava Technologies) and Graph-
Pad Prism 5.0 software (San Diego, CA). A total of 500–1,500
parasites were evaluated in duplicate per compound treatment.
Mammalian cell line-based specificity assays
Mammalian cells were cultured and maintained according to
ATCC specifications (ATCC, Manassas, VA). Cell line drug
susceptibility assays were performed in final volumes of 25 mL
using our previously described 384-well microtiter plate format
[38,39]. Briefly, for automated HTS procedures, cells (A549,
IMR-90 and, HeLa, 1,000 cells; PC-3, 750 cells and; MDA-MB-
231, 3,000 cells) in complete culture medium were seeded into
each well of 384-well microtiter plates using a Titertek MAPC-2
bulk dispenser. Test and control compounds were added to
individual wells as described above. Vehicle and positive controls
were 1% DMSO and 10% DMSO, respectively (final well
concentrations). Assay plates were incubated for 44–46 h at
37uC in the presence of 5% CO2 and growth inhibitory effects
were determined as described above. Five mL of alamar blue
reagent was added to each well and incubated for 2–4 h. Data
were captured as described above.
HTS data analysis, computational filtering, and statistical
analysis
Primary HTS data analysis and subsequent compound EC50
calculations were performed using ActivityBase (IDBS, Guilford, UK)
and Cytominer (University of Pittsburgh Drug Discovery Institute,
Novel Leishmanicidal Assay and Small Molecules
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Pittsburgh, PA). To maximize the diversity of leishmanicidals, we
performed the primary HTS assay at low stringency with 10 mM of
each compound, which ensured a high rate of positive compound
identification. Jarvis-Patrick clustering methodology (Leadscope,
Columbus, OH) was used to computationally filter the number of
compounds that proceeded through secondary hit confirmation
assays [51]. This deterministic and non-iterative methodology
generated non-overlapping, non-hierarchical clusters based on
chemical structural similarities. The algorithm selected the number
of clusters, with each cluster consisting of at least one structure, and
generated non-overlapping, non-hierarchical clusters. A compound
with the smallest maximum pairwise distance to the other cluster
members was selected as the representative for the structural cluster.
In clusters with only two compounds, either compound was selected
to represent its specific cluster. This methodology enabled us to
reduce the number of potential inhibitors to be evaluated from
,20,000 to ,1,200 (0.61% hit rate) while maximizing the chemical
diversity of the primary hit pool. Additional data visualization and
statistical analysis were performed using Graphpad Prism software
5.0 and Spotfire (Somerville, MA). The PubChem database (http://
PubChem.ncbi.nim.nih.gov) was mined to determine if the con-
firmed L. major growth inhibitors exhibited bioactivity in other assays.
In some instances, select compounds were tested in approximately
300 additional assays, including various molecular target based,
phenotypic and cytotoxicity assays. The structural similarity of the
confirmed inhibitors was determined using Leadscope software (i.e.
Tanimoto score).
Predicted drug-like properties of confirmed L. major
growth inhibitors
Confirmed L. major growth inhibitors were filtered further for
desirable drug-like properties using ADME Boxes v4.0 software
(Pharma Algorithms, Toronto, Canada) [52,53]. In brief, this
algorithm predicted human adsorption and metabolism bioavail-
ability for new compounds using a combination of two methods:
probabilistic and mechanistic. A bioavailable compound was
defined as one that should satisfy the following criteria: dissolve in
the stomach or intestine under variable pH, withstand acid
hydrolysis at pH,2, permeate through intestinal membrane by
passive or active transport, withstand P-glycoprotein efflux in
concert with metabolic enzymes in intestine, and withstand first-
pass metabolism in liver. Based on predictions, oral bioavailability
was classified as follows: poor,30%; moderate 30–70%; and good
.70%. The ADME Boxes software also was used to predict
toxicity (i.e. AMES, hERG, skin irritation, LD50 in mice and
Cyp450 inhibition) of compounds. For genotoxicity, we calculated
the probability that a compound would register as a positive in an
Ames mutagenicity screening test while hERG in silico assessment
was calculated as the probability of a compound being a hERG
channel inhibitor at clinically relevant concentrations. Acute
toxicity was estimated as the LD50 value (mg/kg) after intraper-
itoneal, oral, intravenous or subcutaneous administration to mice.
Skin irritation in silico predictions reflected measurements usually
performed in a rabbit Draize test, which primarily measures the
toxicity of a compound intended for topical application, cosmetic
use or possibly coming into contact with human skin at a standard
dose (100 or 500 mg). Toxicity predictions have an associated
Reliability Index (RI) as defined as follows: RI,0.3; not reliable,
RI = 0.3–0.5, borderline reliability; RI= 0.5–0.75, moderate
reliability and RI$0.75, high reliability [53].
In vivo murine CL efficacy studies
Adult female Balb/c mice (6 to 10 week old) were obtained from
(Charles River Laboratories, Wilmington, MA) and maintained as
outlined by the National Institutes of Health Guide for the Care and
Use of Laboratory Animals. All in vivo studies were carried out in
accordance with protocols approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Miami
(IACUC number C01-08). Food and water were supplied ad libitum.
Mice were anesthetized prior to subcutaneous inoculation with 106
stationary phase L. major parasites in 50 mL of Dulbecco’s modified
Eagle medium in the left hind footpad. Animals were examined
daily to determine lesion development. Mice were treated with
experimental compounds at a concentration of 40 or 160 mg/kg in
a 200-mL total volume/mouse. Control mice were injected with an
equivalent amount of vehicle control or amphotericin B (12.5 mg/
kg). Footpad lesion size was measured using a Vernier caliper at 7,
14, and 21 days post-compound administration. Mice were
euthanized in a CO2 chamber at day 21.
Results
HTS assay optimization procedures and validation of the
low stringency screening strategy
The growth characteristics of the L. major promastigotes in a
384-well plate format were first optimized. When promastigotes
were seeded at 105/mL on day 0, the parasite exhibited
conventional exponential, stationary and declining phases over
seven days, as anticipated from previous reports with other plate
formats [54] (Figure S1). All subsequent assay development and
screening studies were performed with exponentially growing L.
major promastigote cultures (,2–36107 promastigotes/mL). Pro-
mastigotes readily tolerated up to 1% DMSO with no degradation
of growth rate, and the optimal incubation time for alamar blue
was 4 h. In the 384-well format, the EC50 for amphotericin B was
207611 nM, consistent with previously published results with L.
major promastigotes in a different assay plate format [41,42].
Similarly, EC50 values from other known leishmanicidals including
paromomycin (19.760.6 mM), pentamidine (0.3660.02 mM) and
sodium stibogluconate (.100 mM) compared favorably to previ-
ously published reports with other Leishmania species [46,55]. An
automated, three-day variability assessment with the L. major
promastigote drug susceptibility assay format produced Z-factors
of .0.5 and .10-fold signal window. The L. major promastigote
drug susceptibility assay was validated for automated HTS
implementation by screening the 1,280 compound LOPAC set.
Each compound was tested in duplicate at a single concentration
(10 mM) and the reproducibility between the duplicate screens is
represented in Figure 1 (R2= 0.94). Average Z-factors were
0.7160.03 for the two LOPAC assays, demonstrating the
robustness of the developed HTS assay format. Significantly,
several compounds with known in vitro and/or in vivo leishmani-
cidal activity were identified as primary hits, including tamoxifen,
pentamidine isethionate, ketoconazole, ivermectin, niclosamide,
clotrimazole, and quinacrine [1,28,29,56–60]. We also found the
leishmanicidal compounds berberine and mycophenolic acid as
primary hits when we screened the UP-CMLD DP validation set
[61,62]. These data confirmed that our optimized L. major
promastigote drug susceptibility HTS assay format could be used
to identify compounds exhibiting in vitro as well as in vivo
leishmanicidal activity.
The percentage of compounds in these two validation assays
that were identified as growth inhibitory was relatively high,
namely 10.5% and 22.6% for the diverse LOPAC and the more
focused UP-CMLD DP sets, respectively, as would be expected
under low stringency conditions. To test whether our screening
strategy was associated with increased chemical diversity, we used
the L. major promastigote drug susceptibility assay to interrogate
Novel Leishmanicidal Assay and Small Molecules
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the UP-CMLD diversity set, which comprised 960 compounds, at
1 and 10 mM. As anticipated, the total number of compounds
identified as potential growth inhibitors at 10 mM was greater than
at 1 mM (250 versus 46) and, importantly, 87% of the compounds
identified as actives ($50% inhibition of signal) at 1 mM were also
found at 10 mM. There were more structural clusters identified at
10 mM (19) than at 1 mM (7), confirming enhanced structural
diversity with the higher screening concentration. Compounds
classified as singletons remained relatively consistent across the
high (8) and low screening concentrations (6), although the
composition of the singleton category changed with increasing
screening concentration. Specifically, only 3 (of the 6) singleton
compounds detected at the 1 mM screening concentration were
represented in the 8 singletons identified at the 10 mM screening
concentration. Thus, we adopted a high throughput, low-
stringency, computationally-enhanced, small molecule screening
(HILCES) strategy to maximize the structural diversity of the
identified leishmanicidals.
Interrogation of 196,146 compounds and computational
enhancement of active chemotypes
We next screened 196,146 compounds at 10 mM in 618 plates.
Performing robustly, the assay had an average Z-factor of 0.960.1
and an average signal to background values of 26.161.0 without
any assay plate failures (Figure S2). Primary hits, defined as
compounds that caused $50% inhibition of the signal readout,
represented 17,629 compounds (an 8.9% hit rate). We next
computationally filtered the number of compounds that would
progress to secondary confirmation assays using a Jarvis-Patrick
clustering methodology. We identified 553 structural clusters
ranging from 2–360 members and 640 compounds as unique
chemical structures (i.e., singletons) (Figure 2). One compound
with the smallest maximum pairwise distance to all other
compounds within a cluster was selected to represent a particular
structural cluster. In the 84 structural clusters consisting of two
compounds, one compound was selected arbitrarily because the
Jarvis-Patrick methodology is based on the similarity between
several neighbors. In total, the 640 singletons and 553 represen-
tative compounds (1,193 compounds) were selected for the L. major
promastigote secondary assays. Initially, compounds were reas-
sayed at 10, 5, and 1 mM to confirm activity and assess potency
quickly. One hundred forty-six compounds exhibited $50%
inhibition when assayed at 1 mM and, therefore, progressed to
secondary confirmation assays. All of these primary screening data
have been posted for public access on the PubChem database
(http://PubChem.ncbi.nlm.nih.gov/).
Initial confirmation of growth inhibitory activity and
expansion of the pool of novel leishmanicidal
chemotypes
The growth inhibitory activity of the 146 compounds was
confirmed using 10-point concentration (0.01–5.00 mM) response
assays. In total, 137 compounds had EC50 values of ,5 mM for an
overall confirmation rate of 93.8%. Of the 137 confirmed L. major
promastigote growth inhibitors, remarkably, 93 compounds had
EC50 values ,1 mM. In initial specificity studies, 70 of the
submicromolar L. major growth inhibitors failed to inhibit the
growth of the sentinel mammalian A549 cell line at 1 mM,
suggesting specificity towards the L. major promastigote (Table S1).
Moreover, because these compounds are part of the publicly
accessible PubChem database, they have to date been screened in
99 (lowest) to 369 (highest) additional phenotypic and target-based
bioassays (Table S1). Sixty-six percent of the leishmanicidal
compounds registered as confirmed actives in #2 PubChem
bioassays. None of the leishmanicidal compounds were structurally
similar to the clinically used anti-leishmanial compounds sodium
Figure 1. Reproducibility of the automated assay format demonstrated with the Library of Pharmacologically Active Compounds
(LOPAC). The robustness of the L. major promastigote drug susceptibility assay was demonstrated by screening the 1,280 compound LOPAC library
in duplicate at 10 mM. The reproducibility between the two assays was R2 = 0.94. Average Z-factors equaled 0.7160.03 with a signal to background
(S:B) ratio of 20.9860.32. (blue circle - test compound; green circle - MAX control; red circle - MIN control; and pink circle - EC50 control).
doi:10.1371/journal.pntd.0000540.g001
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stibogluconate and amphotericin B (Tanimoto score #0.3),
supporting our objective of expanding the pool of potential
leishmanicidal chemotypes (Table S1). Importantly, however,
compounds with previously documented in vivo or in vitro
leishmanicidal activity were also identified using the HILCES
system, including pentamidine isothionate, clotrimazole, amina-
crine, aphidicolin, and acivicin, thus further validating our assay
system (Table 1 and Table S1) [1,42,58,63,64].
Characterization of leishmanicidal activity in L. major
promastigotes and axenic amastigote-like populations
Next, we selected a representative group of 15 chemotypes and
verified their leishmanicidal activity using compounds from a
commercial supplier, thereby controlling for growth inhibitory
effects resulting from any potential compound degradation during
library storage. These compounds were balanced between
compounds with known pharmacological actions (7) and new
chemotypes (8) (Figure 3, Tables 1 and 2). We confirmed the
leishmanicidal activity of the 15 chemotypes (Tables 1 and 2) with
the majority of the compounds registering as submicromolar
growth inhibitors. Significantly, there was a strong correlation
between the EC50 values derived using the alamar blue assay with
determinations using a flow cytometer-based format providing a
second, independent methodology that confirmed the leishmani-
cidal activity of the test compounds (Tables 1 and 2). Subsequent
testing in a human cell line panel indicated that the majority of the
compounds displayed a specific and selective growth inhibitory
effect toward the L. major parasite (Tables 1 and 2). None of the
new chemotypes and only two of the compounds with known
pharmacological actions, sangivamycin (PubChem CID 9549170)
and acivicin (PubChem CID 2007), inhibited the growth of human
cell lines tested (Table 1 and Table 2). Amphotericin B was used as
a reference compound and the results were consistent with
previously reported EC50 values (Table 1) [40,65].
We next determined the leishmanicidal activity of the 15 test
compounds using an L. major axenic amastigote-like alamar blue-
based assay. Thirteen compounds exhibited growth inhibitory
activity, indicating that these compounds were active at pH 4.9.
Significantly, four compounds maintained their submicromolar
activity, with three compounds PubChem CID 3117 (disulfiram),
457964 (aphidicolin) and 760847, exhibiting EC50 values compa-
rable to amphotericin B (Table 1 and Table 2). Several other
compounds displayed EC50 values #10 mM.
Additional filtering of compounds by in silico predictive
analyses
The 15 test compounds were further classified for potential in
vivo studies with respect to in silico predictive ADMET character-
istics (Table S1). Twelve compounds had predicted bioavailability
profiles in the good to moderate range while three compounds
were predicted to have poor bioavailability. Overall, the 15 test
compounds were not predicted to exhibit significant toxicity;
however, two compounds (CID 786799 and 742546) have high
probability for skin irritation while one compound (CID 2812) has
a moderate probability of inhibiting Cyp3A4 at 10 and 50 mM
(Table S1).
In vivo leishmanicidal activity of disulfiram
To determine if any of the new leishmanicidal chemotypes
identified in the L. major promastigote screen had in vivo activity, we
prioritized compounds according to the empirically-derived
potency and specificity data, known pharmacological activity,
activity in the L. major axenic amastigote-like drug susceptibility
assay, in silico predicted ADMET, previous human usage, and
novelty of the leishmanicidal chemotype. Thus, disulfiram was
selected for initial in vivo efficacy studies. L. major-infected Balb/c
mice were treated with vehicle, disulfiram (40 or 160 mg/kg), or
amphotercin B (12.5 mg/kg) for 21 days. Drug treatment was
Figure 2. Frequency distribution of primary hit structural clusters. Active compounds identified in primary HTS activities were subjected to
computational filtering by Leadscope to decrease the number of compounds entering secondary screening activities. After analyses, 553 structural
clusters were identified with cluster sizing ranging from 2–360 compounds. Six hundred and forty compounds could not be assigned to a structural
cluster and were classified as singletons.
doi:10.1371/journal.pntd.0000540.g002
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Figure 3. Chemical structures of test compounds. Structures of the 15 representative compounds tested empirically. Panel A, Compounds of
known pharmacological action. Panel B, Compounds of unknown pharmacological action.
doi:10.1371/journal.pntd.0000540.g003
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initiated 3 days post-infection allowing for the establishment of the
leishmaniasis infection. Over the course of the 10 day treatment, a
decrease in the average footpad thickness was observed as
compared with vehicle treated animals. With disulfiram
(160 mg/kg) treatment, there was a ,43% and 50% reduction
in footpad thickness observed on days 14 and 21 post-infection,
respectively (Figure 4). There was a similar decrease observed in
footpad thickness with 40 mg/kg disulfiram on days 14 (25%) and
21 (35%), illustrating a dose- and time-dependent efficacy of the
disulfiram treatment. As expected, the amphotericin B (12.5 mg/
kg) control treatment effectively reduced footpad swelling and
these data were consistent with additional experiments that
showed an average 80–85% reduction in footpad swelling after
amphotericin B treatment (Figure 4 and data not shown).
Although disulfiram and amphotericin B display similar levels of
growth inhibitory activity in the promastigote and axenic
amastigote-like assays, there was a difference in their in vivo effects
(i.e., 50% versus ,85–90% reduction in footpad swelling). This
disparity in in vivo effects may be the result of differences in
bioavailability or mechanism of action.
Discussion
In the current study, we illustrate the power of HILCES, a low
stringency, ’’forward’’ pharmacology, antileishmanial drug discov-
ery strategy that employs a robust phenotypic HTS assay
unencumbered by concerns for specific molecular targets [66].
HTS methodologies enabled the interrogation of a large diverse
compound library, and when linked with computational method-
ologies, permitted refinement of the primary screening data by
chemical structural clustering of chemotypes and predicted
pharmacological attributes. This HILCES strategy enhanced our
ability to identify novel leishmanicidal chemotypes, and, as a
result, enabled us to test these new chemotypes for in vivo
leishmanicidal activity, thus effectively expanding the pool of
chemical structures that could be refined as potential leishmani-
cidal therapies. By capitalizing on multiple assay formats as well as
L. major promastigote and axenic amastigote-like life cycle forms,
we were able to confirm and prioritize our L. major growth
inhibitory chemotypes for in vivo testing. Significantly, our
preliminary studies with disulfiram indicated that our HTS and
hit confirmation strategy could lead to the identification of novel
leishmanicidal chemotypes with in vivo efficacy.
L. major promastigotes have frequently been used to characterize
the growth inhibitory activity of potential leishmanicidal agents
and they are well suited for the rapid screening of large chemical
libraries due to ease of culturing [44]. In fact, two smaller scale
screens, ,2,100 compounds (http://www.sandler.ucsf.edu/lhf)
and ,15,000 compounds [67] have been performed using
Leishmania promastigotes. Moreover, there is some evidence that
the promastigote form of the parasite is an effective and reliable
indicator of a compound’s leishmanicidal activity in cell-based and
axenic amastigotes except when examining immunomodulating
anti-leishmanial compounds, such as sodium stibogluconate and
meglumine antimoniate [40,55,68,69]. Nonetheless, we acknowl-
edge that there continues to be some debate about the
physiological relevance of the L. major promastigote as an indicator
of leishmanicidal activity for the cell-internalized amastigote form
of the parasite, primarily because it is not the parasite stage found
in humans, and they have a dissimilar response to the pentavalent
antimonial compounds [40,44]. Even so, we suggest that the
promastigote-based screening assay may effectively function as the
foundation for a comprehensive screening paradigm that is
designed to identify and qualify novel leishmanicidal chemotypes.
Table 2. Effects of compounds of unknown pharmacological action on L. major promastigotes and axenic amastigote-like
populations.
Compound
(Pubchem CID)
L. major promastigote EC50 (mM)
(AVE6SD) Confirmation Alamar Blue
L. major promastigote EC50 (mM) (AVE6SD)
Confirmation Flow cytometry
L. major axenic amastigote-like EC50 (mM)
(AVE6SD) Confirmation Alamar Blue
786799 1.2660.08 2.2260.11 3.660.13
742546 0.6960.04 0.4360.30 .50
760847 0.1960.02 0.2060.05 0.2160.09
2946668 0.8660.16 0.3560.06 1.260.4
757789 2.0460.08 1.9460.15 3.260.8
2851545 0.2160.02 0.3460.48 11.760.5
728862 3.6360.96 1.7760.12 4.360.8
16187595 0.0160.002 0.0460.01 2.360.2
doi:10.1371/journal.pntd.0000540.t002
Figure 4. In vivo efficacy of disulfiram in a murine footpad
model. Balb/c mice were infected with 106 stationary phase L. major
promastigotes (s.c.) and treated three days later with vehicle (open
square), disulfiram (160 mg/kg)(black square) or amphotericin B (gray
square). Footpad thickness was measured every 7 days over a 21 day
period. Data are presented as mean6SEM (n= 5).
doi:10.1371/journal.pntd.0000540.g004
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We recognize, however, the significance of the ability to perform
HTS in a cell-based amastigote system (http://www.dndi.org/
newsletters/n18/5_1.php).
The use of a publicly available annotated chemical library
enabled us to cross-query a range of archived bioassays and to
consider potential novel molecular targets. While the majority of
the leishmanicidals failed to register as confirmed actives in other
assays (Table S1), suggesting specificity for leishmanicidal activity,
we found several compounds that affected previously unappreci-
ated and provocative potential L. major molecular targets. For
example, we found protein targets involved with cell proliferation,
differentiation, invasion and motility, such as protein kinase D
(gene id 5587), protein kinase C (gene id 5578), polo-like kinase 1
(gene id 5347), steroidogenic factor 1 (gene id 2516) and
phosphatase regenerating liver-1 (gene id 7803) [70–74]. Signif-
icantly, these or related proteins are not only expressed in L. major
but also in other parasites, including Schistosoma mansoni and
Trypanosoma brucei, so they might also be critical for schistosome
and trypanosome growth, differentiation, cell cycle regulation,
motility and viability [31,75–77]. Moreover, these data suggest
that compound libraries used in conjunction with genome searches
may be exploited to identify potential new drug targets.
In summary, we identified 70 submicromolar compounds that
inhibit promastigote growth by using HILCES with a publicly
available annotated library. Significantly, these compounds did
not inhibit mammalian cell growth in companion counter-
screening assays, suggesting an L. major-specific inhibitory
response. All of the primary screening data are accessible on
PubChem (http://PubChem.ncbi.nlm.nih.gov) and can be con-
veniently mined worldwide to allow for further refinement of
individual compounds. A novel leishmanicidal chemotype, disul-
firam, exhibited up to 50% in vivo efficacy in our animal model
system. Disulfiram validated our compound screening strategy, it
has a number of potential molecular targets and mechanisms.
Several of the identified compounds have known molecular targets
that may be relevant for this and other Leishmania species. The
simple platform developed for L. major may also be useful for efforts
designed to identify chemotherapeutics for other Leishmania
species.
Supporting Information
Figure S1 L. major promastigote growth curve exhibits charac-
teristic exponential, stationary and decline phases. To develop and
validate our HTS assay, we defined the growth characteristics of
the L. major promastigote. Promastigotes were seeded at 105
parasites per mL on day 0 and the number of parasite determined
for seven days. (1) Exponential growth phase; (2) Stationary
growth phase; and (3) Decline. (n = 2, bars = range).
Found at: doi:10.1371/journal.pntd.0000540.s001 (0.18 MB TIF)
Figure S2 HTS statistics from the primary screen. Z-factors and
signal to back grounds for all 618 primary screening assay plates.
Found at: doi:10.1371/journal.pntd.0000540.s002 (0.40 MB TIF)
Table S1 Confirmed leishmanicidal compounds as identified
from the L. major HTS assay using the PMLSC library. ADMET -
Adsorption, distribution, metabolism, excretion and toxicity; Ames
- Ames test; hERG inhibition; RI - Reliability Index of in silico
predicted data; SI - Skin irritation; OB - Oral bioavailability;
LD50 - half maximal lethal dose; IP - intraperitoneal, OR - Oral,
IV - intravenous, or SC - Subcutaneous administration; Tanimoto
similarity score - method of calculating the similarity between
chemical structures, SSG - sodium stibogluconate and AB -
amphotericin B; AID - Assay identifier.
Found at: doi:10.1371/journal.pntd.0000540.s003 (0.26 MB PDF)
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